Buparlisib (BKM120), an oral pan‐class I PI3K inhibitor, has shown potential in phase II trials for advanced breast cancer [26], glioblastoma [27] and head and neck squamous cell carcinoma (HNSCC) [28]. Here, PIK3CA is linked to breast cancer.